Author

S. Panja

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Lucas· 2 shared K. Mallela· 2 shared V. Upadhyay· 2 shared A. A. Hamid· 1 shared A. D. Choudhury· 1 shared A. Mitrofanova· 1 shared A. S. Kibel· 1 shared A. Sowalsky· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

A. Lucas

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Biophysical evolution of the receptor binding domains of SARS-CoVs

V. Upadhyay, S. Panja, A. Lucas, C. Patrick, K. Mallela

This study compares the biophysical properties of SARS-CoV and SARS-CoV-2 receptor binding domains, finding differences in stability, aggregation, and ACE2 binding affinity.

bioRxiv · Jun 13, 2023Biophysics

Interplay between receptor binding, immune escape and protein stability determines the natural selection of SARS-CoV-2 variants

V. Upadhyay, A. Lucas, S. Panja, R. Miyauchi, K. Mallela

The paper evaluates how mutations in SARS-CoV-2's receptor binding domain affect protein stability, ACE2 binding, and antibody escape, showing multiple factors influence variant selection.

bioRxiv · May 23, 2021Biophysics

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

bioRxiv · Aug 8, 2019 · PreprintCancer Biology